Maintenance therapy for PJP in patients with hypersensitivity to trimethoprim+sulfamethoxazole

Alternatives for maintenance therapy for PJP are less effective than trimethoprim+sulfamethoxazole.

Assess patients with PJP who report hypersensitivity to trimethoprim+sulfamethoxazole:

Desensitisation is an option for clinically stable patients who report hypersensitivity to trimethoprim+sulfamethoxazole – seek expert advice if desensitisation is being considered. Do not desensitise patients:

  • with severe delayed1 hypersensitivity
  • in whom adherence to therapy is unlikely – if 1 day of therapy is missed, the patient’s hypersensitivity will return and desensitisation must be performed again.

Following trimethoprim+sulfamethoxazole desensitisation, use the daily regimen of trimethoprim+sulfamethoxazole rather than the twice- or 3-times-weekly regimensLiu 2011.

If desensitisation is not an option, see the alternative maintenance therapy options for PJP in adults or children.

Note: Assess patients reporting hypersensitivity to trimethoprim+sulfamethoxazole.
1 Severe delayed hypersensitivity reactions include cutaneous adverse drug reactions (eg drug rash with eosinophilia and systemic symptoms [DRESS], Stevens–Johnson syndrome/toxic epidermal necrolysis [SJS/TEN], severe blistering or desquamative rash), and significant internal organ involvement (eg acute interstitial nephritis).Return